Acromegaly and its Treatment

Session

Medical, Chemical and Pharmaceutical Sciences

Description

Acromegaly is a hormonal disorder which results when pituitary adenoma produces more growth hormone (GH). The most common symptoms of acromegaly are: severe face, thickening of soft tissues such as the face, typical hands like "shovels", jaw is more forward (Prognathism), sweating, impaired glucose tolerance or diabetes mellitus. The treatment focuses on lowering GH production, as well as reducing the negative effects of the tumor in the pituitary gland and surrounding tissues. Doctors can remove the pituitary tumor by using a method called transfenoid surgery with radiation. The medicines used to reduce the production or block the action of GH include: Somatostatin analogs, dopamine agonists, GH antagonists: Pegvisomant or Somavert, an analog of human growth hormone (GH) which is structurally modified to act as an antagonist GH receptor. Pegvisomant is a recombinant DNA protein containing 191 amino acid residues. Pegvisomant is synthesized by a specific origin of Escherichia Coli bacteria, which has been genetically modified by the addition of a plasmid that carries a gene for the antagonists of GH receptor. Somavert is available in a single dose, sterile bottle containing 10, 15, or 20 mg of pegvisomant protein. Each bottle also contains 1.36 mg glycine, 36.0 mg manitol, 1.04 mg sodium phosphate anhydrous, and 0.36 mg phosphate sodium monohydrate miono-basic. Get emergency medical help if you have any signs of an allergic reaction. Do not use pegvisomant if you have a serious side effect.

Keywords:

Acromegaly, pegvisomant

Session Chair

Arianit Jakupi

Session Co-Chair

Valon Ejupi

Proceedings Editor

Edmond Hajrizi

ISBN

978-9951-437-54-7

Location

Durres, Albania

Start Date

28-10-2017 9:00 AM

End Date

28-10-2017 10:30 AM

DOI

10.33107/ubt-ic.2017.294

This document is currently not available here.

Share

COinS
 
Oct 28th, 9:00 AM Oct 28th, 10:30 AM

Acromegaly and its Treatment

Durres, Albania

Acromegaly is a hormonal disorder which results when pituitary adenoma produces more growth hormone (GH). The most common symptoms of acromegaly are: severe face, thickening of soft tissues such as the face, typical hands like "shovels", jaw is more forward (Prognathism), sweating, impaired glucose tolerance or diabetes mellitus. The treatment focuses on lowering GH production, as well as reducing the negative effects of the tumor in the pituitary gland and surrounding tissues. Doctors can remove the pituitary tumor by using a method called transfenoid surgery with radiation. The medicines used to reduce the production or block the action of GH include: Somatostatin analogs, dopamine agonists, GH antagonists: Pegvisomant or Somavert, an analog of human growth hormone (GH) which is structurally modified to act as an antagonist GH receptor. Pegvisomant is a recombinant DNA protein containing 191 amino acid residues. Pegvisomant is synthesized by a specific origin of Escherichia Coli bacteria, which has been genetically modified by the addition of a plasmid that carries a gene for the antagonists of GH receptor. Somavert is available in a single dose, sterile bottle containing 10, 15, or 20 mg of pegvisomant protein. Each bottle also contains 1.36 mg glycine, 36.0 mg manitol, 1.04 mg sodium phosphate anhydrous, and 0.36 mg phosphate sodium monohydrate miono-basic. Get emergency medical help if you have any signs of an allergic reaction. Do not use pegvisomant if you have a serious side effect.